Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from OS Therapies Incorporated ( (OSTX) ) is now available.
On August 25, 2025, OS Therapies announced the termination of its Equity Purchase Agreement with Square Gate Capital, effective August 26, 2025. This decision follows the company’s successful warrant exercise inducement, which raised $4.2 million to fund operations into mid-2026. With reduced projected expenses due to completed clinical trials, OS Therapies plans to focus on obtaining approval for OST-HER2 in osteosarcoma and analyzing data for OST-504 in prostate cancer.
The most recent analyst rating on (OSTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies is a clinical-stage oncology company focused on developing treatments for osteosarcoma and other solid tumors. Their lead asset, OST-HER2, is an immunotherapy targeting the HER2 protein and has received multiple designations from the U.S. FDA and European Medicines Agency. The company is also advancing its tunable Antibody Drug Conjugate (tADC) platform.
Average Trading Volume: 574,236
Technical Sentiment Signal: Strong Buy
Current Market Cap: $69.84M
For an in-depth examination of OSTX stock, go to TipRanks’ Overview page.